-
公开(公告)号：US20240318185A1
公开(公告)日：2024-09-26
申请号：US18607162
申请日：2024-03-15
发明人： Carl Randall Harrell
IPC分类号： C12N15/113 , A61K35/28 , A61K45/06 , A61P35/00 , A61P37/04
CPC分类号： C12N15/1138 , A61K35/28 , A61K45/06 , A61P35/00 , A61P37/04 , C12N2310/141
摘要： Disclosed herein are compositions, formulations, and/or methods of using mesenchymal stem cells (MSCs) and/or MSC-derived products (such as, for instance, MSC-derived exosomes (MSC-Exos) and/or MSC-derived micro-ribonucleic acids (miRNAs)) for preventing and treating cancer, and for suppressing the growth or proliferation of cancer. Upon administration to a subject, the MSC-derived miRNAs can suppress tumor growth and progression by: (i) upregulating expression of one or more chemoresistance-related genes in one or more tumor cells, (ii) reducing the viability and/or invasiveness of one or more malignant cells, (iii) suppressing neo-angiogenesis in the tumor microenvironment, and/or (iv) inducing generation, proliferation, and/or tumorotoxicity of one or more immune cells (e.g., cytotoxic T lymphocytes (CTLs) and/or natural killer T (NKT) cells). In at least one embodiment, one or more MSC-derived miRNAs are contained within one or more MSC-Exos, which are used in combination with, or formulated with, one or more additional active agents.
-
公开(公告)号：US11633432B2
公开(公告)日：2023-04-25
申请号：US16023041
申请日：2018-06-29
发明人： Carl Randall Harrell
摘要： A human amniotic fluid formulation has been developed for topical application to the eye, which is useful for the treatment of ocular diseases and injuries including dry eyes, Sjogren's Syndrome, cataracts, burns and injuries to the eye tissues. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles. Methods for treating, or preventing various ocular diseases, injuries and disorders using the formulation, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents are described.
-
公开(公告)号：US20230021477A1
公开(公告)日：2023-01-26
申请号：US17933374
申请日：2022-09-19
发明人： Carl Randall Harrell
摘要： Formulations of human amniotic fluid and methods of use thereof for treatment of chronic lung disorders have been developed. The formulations are suitable for topical delivery to the lung, for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-I antitrypsin emphysema. Methods including administering specifically formulated, diluted sterile decellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 μm to about 5 μm, preferably from about 2.5 μm to about 3.5 μm, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described. Formulations described can treat, or prevent one or more symptoms of a chronic lung disorder
-
公开(公告)号：US20180311284A1
公开(公告)日：2018-11-01
申请号：US16023041
申请日：2018-06-29
发明人： Carl Randall Harrell
CPC分类号： A61K35/50 , A61K9/0048 , A61K9/0051 , A61K9/08 , A61K9/19 , A61K47/10
摘要： A human amniotic fluid formulation has been developed for topical application to the eye, which is useful for the treatment of ocular diseases and injuries including dry eyes, Sjogren's Syndrome, cataracts, burns and injuries to the eye tissues. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles. Methods for treating, or preventing various ocular diseases, injuries and disorders using the formulation, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents are described.
-
公开(公告)号：US20180126033A9
公开(公告)日：2018-05-10
申请号：US15069537
申请日：2016-03-14
发明人： Carl Randall Harrell
CPC分类号： A61L27/24 , A61K35/50 , A61K38/39 , A61K45/06 , A61L27/3604 , A61L27/362 , A61L27/3687 , A61L27/3804 , A61L27/54 , A61L27/60 , A61L2400/06 , A61L2430/18 , A61L2430/34 , A61L2430/40
摘要： Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.
-
公开(公告)号：US20170354692A1
公开(公告)日：2017-12-14
申请号：US15290271
申请日：2016-10-11
发明人： Carl Randall Harrell
CPC分类号： A61K35/50 , A61H23/02 , A61H2033/143 , A61H2205/084 , A61K9/0078 , A61K45/06
摘要： Formulations of human amniotic fluid and methods of use thereof for treatment of lung disorders, and/or injuries have been developed. The formulations are suitable for topical delivery to the lung for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-1 antitrypsin emphysema, as well as for treatment of acute lung injuries. Methods including administering specifically formulated, diluted sterile de-cellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular, the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 μm to about 5 μm, preferably from about 2.5 μm to about 3.5 μm, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described. Formulations described can treat, or prevent one or more symptoms of a chronic lung disorder.
-
公开(公告)号：US20230270916A1
公开(公告)日：2023-08-31
申请号：US18121384
申请日：2023-03-14
发明人： Carl Randall Harrell
IPC分类号： A61L27/24 , A61K38/39 , A61K35/50 , A61K45/06 , A61L27/54 , A61L27/36 , A61L27/38 , A61L27/60
CPC分类号： A61L27/24 , A61K38/39 , A61K35/50 , A61K45/06 , A61L27/54 , A61L27/3604 , A61L27/362 , A61L27/3687 , A61L27/3804 , A61L27/60 , A61L2430/18 , A61L2430/34 , A61L2400/06 , A61L2430/40
摘要： Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.
-
公开(公告)号：US11491189B2
公开(公告)日：2022-11-08
申请号：US15876988
申请日：2018-01-22
发明人： Carl Randall Harrell
摘要： Formulations of human amniotic fluid and methods of use thereof for treatment of lung disorders, and/or injuries have been developed. The formulations are suitable for topical delivery to the lung for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-1 antitrypsin emphysema, as well as for treatment of acute lung injuries. Methods including administering specifically formulated, diluted sterile de-cellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular, the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 μm to about 5 μm, preferably from about 2.5 μm to about 3.5 μm, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described. Formulations described can treat, or prevent one or more symptoms of a chronic lung disorder.
-
公开(公告)号：US11273183B2
公开(公告)日：2022-03-15
申请号：US15912096
申请日：2018-03-05
发明人： Carl Randall Harrell
IPC分类号： A61K35/50 , A61K9/14 , A61K9/00 , A61L31/16 , A61L31/00 , A61L27/54 , A61L27/36 , A61P19/02 , A61P19/00 , A61K38/18 , A61P19/10 , A61K9/08 , A61K45/06 , A61K9/19
摘要： A human amniotic fluid formulation has been developed for administration into a joint or associated soft tissue such as a tendon or ligament for treatment of pain, degeneration or injury. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles, which has not been heat treated or treated with ethidium bromide. The formulation is optionally diluted, or concentrated, depending on he severity of the disorder or injury. Examples demonstrate efficacy in treatment of pain, disease, disorder, degeneration or injury of a joint or associated soft.
-
公开(公告)号：US20200077987A1
公开(公告)日：2020-03-12
申请号：US16683939
申请日：2019-11-14
发明人： Carl Randall Harrell
摘要： Provided herein is a pre-Caesarean method for collecting amniotic fluid from a patient. A needle is inserted into the incision site for the future C-section, which may be under ultrasound guidance, through which the amniotic fluid is drawn under a low level suction and, optionally, gravity to a sterile collection container. The method encompasses filtering and/or irradiating the amniotic fluid to collect biomolecules of interest such as growth factors and/or stem cells. Also provided is the sterile amniotic fluid or filtrates thereof collected by the method described herein
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.024 秒)
